Bain Capital Life Sciences Investors, LLC
CIK: 0001703031Latest portfolio: $1.3B · Q4 2025
Holdings
19
Total Value
$1.3B
New Positions
0
Closed Positions
2
Top Holdings
| # | Stock | Shares | Value | % Portfolio | Change | Type |
|---|---|---|---|---|---|---|
| 1 | HTFLHEARTFLOW INC | 12,448,158 | $362.9M | 27.79% | — | |
| 2 | NAMSNEWAMSTERDAM PHARMA COMPANY | 7,306,566 | $256.3M | 19.63% | -3,412,544 | |
| 3 | OLMAOLEMA PHARMACEUTICALS INC | 8,508,641 | $212.7M | 16.29% | +1.7M | |
| 4 | YB4PSAVARA INC | 17,600,621 | $106.1M | 8.13% | — | |
| 5 | PHVSPHARVARIS N V | 2,802,081 | $77.8M | 5.96% | -379,194 | |
| 6 | SLDBSOLID BIOSCIENCES INC | 7,911,669 | $44.6M | 3.42% | — | |
| 7 | UPBUPSTREAM BIO INC | 1,329,544 | $36.1M | 2.76% | -1,109,994 | |
| 8 | XFORX4 PHARMACEUTICALS INC | 7,967,454 | $31.9M | 2.44% | +5.5M | |
| 9 | DNTHDIANTHUS THERAPEUTICS INC | 743,592 | $30.6M | 2.35% | -572,300 | |
| 10 | KYTXKYVERNA THERAPEUTICS INC | 3,110,000 | $29.2M | 2.24% | -258,370 | |
| 11 | ANNXANNEXON INC | 5,249,069 | $26.4M | 2.02% | — | |
| 12 | RPIDRAPID MICRO BIOSYSTEMS INC | 8,434,560 | $24.5M | 1.87% | — | |
| 13 | CABACABALETTA BIO INC | 9,677,125 | $21.2M | 1.62% | — | |
| 14 | CCCCC4 THERAPEUTICS INC | 7,171,910 | $13.7M | 1.05% | +6.1M | |
| 15 | MRSNMERSANA THERAPEUTICS INC | 346,545 | $10.0M | 0.77% | — | |
| 16 | AVIRATEA PHARMACEUTICALS INC | 2,485,638 | $8.9M | 0.68% | — | |
| 17 | TNGXTANGO THERAPEUTICS INC | 653,493 | $5.8M | 0.44% | -2,058,515 | |
| 18 | XLOXILIO THERAPEUTICS INC | 7,372,686 | $4.7M | 0.36% | +2.8M | |
| 19 | NAMSNEWAMSTERDAM PHARMA COMPANY | 99,999 | $2.3M | 0.18% | -1 |
Quarterly Changes
Sector Breakdown
Healthcare0.0% ($3.6286325631421276e+74T)
Unknown0.0% ($10.6T)
Filing History
| Quarter | Filing Date | Portfolio Value | Holdings |
|---|---|---|---|
| Q4 2025 | Feb 17, 2026 | $1.3B | 19 |
| Q3 2025 | Nov 14, 2025 | $1.5T | 21 |
| Q2 2025 | Aug 14, 2025 | $799.3B | 23 |
| Q1 2025 | May 15, 2025 | $675.9B | 24 |
| Q4 2024 | Feb 14, 2025 | $850.1B | 26 |
| Q3 2024 | Nov 14, 2024 | $961.2T | 24 |
| Q2 2024 | Aug 12, 2024 | $910.8T | 25 |
| Q1 2024 | May 15, 2024 | $1244.3T | 26 |
| Q4 2023 | Feb 13, 2024 | $1043.3T | 27 |
| Q3 2023 | Nov 14, 2023 | $894.2T | 31 |
| Q2 2023 | Aug 14, 2023 | $971.0T | 32 |
| Q1 2023 | May 15, 2023 | $800.1B | 34 |
| Q4 2022 | Feb 14, 2023 | $894.8B | 33 |
| Q3 2022 | Nov 14, 2022 | $837.8B | 33 |
| Q2 2022 | Aug 15, 2022 | $852.7B | 35 |
| Q1 2022 | May 16, 2022 | $1.0T | 34 |
| Q4 2021 | Feb 14, 2022 | $1.3T | 34 |
| Q3 2021 | Nov 15, 2021 | $1.6T | 33 |
| Q2 2021 | Aug 16, 2021 | $1.5T | 30 |
| Q1 2021 | May 17, 2021 | $1.8T | 31 |
| Q4 2020 | Feb 16, 2021 | $1.6T | 26 |
| Q3 2020 | Nov 16, 2020 | $1.1T | 22 |
| Q2 2020 | Aug 14, 2020 | $954.8B | 15 |
| Q1 2020 | May 15, 2020 | $591.3B | 11 |
| Q4 2019 | Feb 14, 2020 | $670.5B | 10 |
| Q3 2019 | Nov 14, 2019 | $388.4B | 7 |
| Q2 2019 | Aug 14, 2019 | $196.9B | 5 |
| Q1 2019 | May 15, 2019 | $250.1B | 6 |
| Q4 2018 | Feb 14, 2019 | $292.6B | 6 |
| Q3 2018 | Nov 14, 2018 | $440.6B | 6 |
| Q2 2018 | Aug 14, 2018 | $319.1B | 5 |
| Q1 2018 | May 15, 2018 | $169.6B | 4 |
| Q4 2017 | Feb 14, 2018 | $152.4B | 3 |
Fund Information
Bain Capital Life Sciences Investors, LLC is an institutional investment manager that files 13F reports with the SEC. As of the Q4 2025 filing, the fund reported a portfolio valued at $1.3B across 19 holdings. The largest position is HEARTFLOW INC (HTFL), representing 27.8% of the portfolio. Compared to the previous quarter, the fund opened 0 new positions and closed 2 positions. 13F filings are required quarterly disclosures that provide transparency into the holdings of institutional investment managers with at least $100 million in qualifying assets.